Institut National De La Sante Et De La Recherche Medicale

Universitë De Bordeaux

Ecole Des Hautes Etudes En Sante Publique (ehesp)

Centre National De La Recherche Scientifique

Université De Rennes 1

University of Nottingham

Université De Rennes

Universite Des Antilles Et De La Guyane

Institut Bergonie

Université Paul Sabatier (toulouse Iii)

Université De Bourgogne

Centre Hospitalier Universitaire De Toulouse

Centre Hospitalier Universitaire De Bordeaux

Université De Rennes I

Institute Bergonie

Patrick Legembre

Pierre Vacher

Doriane Sanseau

Pierre Van De Weghe

Aubin Penna

Robin Flynn

Bruno Segui

Thierry Levade

Mickael Jean

Amélie Fouque

Patrick Blanco

Olivier Micheau

The present invention relates the field of reducing CD95-mediated cell motility in a subject, in particular for their use in the reduction of CD-95 mediated cancer cell motility, the reduction of CD95-mediated lymphocyte motility and/or B cell maturation, or the treatment of B-cell tumors, in a subject. The inventors identified a novel family of compounds having the ability to disrupt CD95/PLCγ1 interaction and to neutralize the CD95-mediated calcium signaling pathway and cell migration in human peripheral blood lymphocytes (PBLs) and Th17 cells. Thus, the present invention relates to compounds of formula (A) as defined in the present text, to a pharmaceutical composition comprising said compounds in a pharmaceutically acceptable medium and to the use of these compounds and compositions as medicament, in particular for their use in the reduction or treatment of the above-mentioned pathologies, and in particular in the treatment of cancers and autoimmune inflammatory disease such as systemic lupus erythematosus, inflammatory condition and Th17-mediated disease.

Compounds and pharmaceutical compositions for reducing CD95-mediated cell motility

The present invention relates to polypeptides and uses thereof for reducing CD95-meditated cell motility. In particular, the present invention relates to a polypeptide having an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino-acid residue at position 175 to the amino-acid residue at position 191 in SEQ ID NO:1.

Polypeptides and uses thereof for reducing CD95-mediated cell motility

The present invention relates to methods and pharmaceutical compositions for preventing or reducing metastatic dissemination (i.e. reducing motility of cancer cells). In particular, the present invention relates to a method for preventing or reducing metastatic dissemination (i.e. reducing motility of cancer cells) in a subject suffering from a cancer comprising the steps consisting of i) determining the expression level of at least one biomarker selected from the group consisting of soluble CD95L and EMT promoting factors in a sample obtained from the subject, ii) comparing the expression level determined at step i) with a predetermined reference value and iii) administering the subject with a therapeutically effective amount of C16-ceramide or derivatives such as C16-sphingomyelin and C16-glycosphingolipids when the expression level determined at step i) is higher than the predetermined reference value.

Methods and pharmaceutical compositions for preventing or reducing metastatic dissemination

The invention relates to new PI3K/AKT/m TOR inhibitors and their use for the prevention and/or the treatment of a disease selected from the group consisting of: inflammatory diseases, autoimmune diseases, neurodegenerative diseases, cancers, transplant rejection, diseases characterized by a premature aging and tuberous sclerosis.

PI3K/AKT/mTOR inhibitors and pharmaceutical uses thereof

Growing community of inventors

Rennes, France

Patrick Legembre